Search

Displaying results 3701 - 3710 of 9706 in total
  1. Drug

    Covax-19™

    go.drugbank.com/drugs/DB15846
    Investigational

    Covax-19™, a protein-based vaccine, was developed through partnership between APC and Vaxine. It uses an insect-cell-produced recombinant SARS-CoV-2 spike protein and Vaxine’s adjuvant, Advax-SM.

  2. Drug

    Gam-COVID-Vac

    go.drugbank.com/drugs/DB15848
    Investigational

    The vaccine is offered in both a frozen (Gam-COVID-Vac) and freeze-dried formulation (lyophilizate; Gam-COVID-Vac Lyo). … Preliminary results suggested that all participants developed antibodies to the SARS-CoV-2 glycoproteins with a good safety profile in both trials.

  3. Drug

    SARS-CoV-2 Sclamp

    go.drugbank.com/drugs/DB15849
    Investigational

    The vaccine was developed using UQ’s rapid response ‘molecular clamp’ vaccine platform that locks surface proteins in a configuration that allows more robust immune responses, in combination with a well-established … Preclinical trials showed the vaccine candidate produced high levels of neutralizing antibodies, and induced a strong T-cell response.

  4. Drug

    IMM-101

    go.drugbank.com/drugs/DB15850
    Investigational

    IMM-101 is a heat-inactivated immune-activating mycobacterial product. … As of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over

  5. Drug

    Coronavirus-Like Particle COVID-19 Vaccine

    go.drugbank.com/drugs/DB15852
    Experimental

    A Phase 1 clinical trial was launched in July 2020 evaluating the safety, tolerability, and immunogenicity of this vaccine candidate with or without either Cpg 1018 or AS03 (NCT04450004) in adults aged

  6. Drug

    RUTI® Vaccine

    go.drugbank.com/drugs/DB15853
    Investigational

    Much like the BCG vaccine, the RUTI® vaccine is also being tested as a prophylactic for SARS-CoV2. … The vaccine has demonstrated a reasonable safety profile and potent stimulation of the immune response against tuberculosis.

  7. Drug

    Autologous Non-Hematopoietic Peripheral Blood Stem Cells

    go.drugbank.com/drugs/DB15867
    Investigational

    Autologous non-hematopoietic peripheral blood stem cells have been created into a formulation for use in a clinical trial (NCT04473170) by the Abu Dhabi Stem Cells Center.

  8. Drug

    Cetyltrimethylammonium naproxenate

    go.drugbank.com/drugs/DB15877
    Experimental

  9. Drug

    Methylisothiazolinone

    go.drugbank.com/drugs/DB15884
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    XAV-19

    go.drugbank.com/drugs/DB15895
    Investigational

    As of July, 2020, the company is conducting a Phase 2 randomized clinical trial to define dosing safety and efficacy of XAV-19 (NCT04453384). … However, rather than using human plasma, XAV-19 is a heterologous swine glyco-humanized polyclonal antibody that targets the spike protein of SARS-CoV-2[L16553,L16558].